Quantcast

Latest Alkylating antineoplastic agents Stories

2014-09-16 20:27:26

St. Jude Children's Research Hospital study has identified the cumulative dose of a widely used class of chemotherapy drugs that leaves young male cancer patients at risk for impaired sperm production as adults MEMPHIS, Tenn., Sept. 16, 2014 /PRNewswire-USNewswire/ -- A study led by St. Jude Children's Research Hospital investigators has found the chemotherapy dose threshold below which male childhood cancer survivors are likely to have normal sperm production. The study appears in...

2014-08-05 23:00:31

LifeScienceIndustryResearch.com adds latest Report on “Global and Chinese Cisplatin (CAS 15663-27-1) Industry, 2009-2019 Market Research Report” to its store. Inquire before buying at http://www.lifescienceindustryresearch.com/inquire-before-buying?rname=15033. Dallas, TX (PRWEB) August 06, 2014 Delivery of the Report will take 2-3 working days once order is placed. Global and Chinese Cisplatin (CAS 15663-27-1) Industry, 2009-2019 Market Research Report is a professional and in-depth...

2014-06-30 13:06:13

European Society for Medical Oncology ESMO 16 World GI Congress on Gastrointestinal Cancer The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. "Around 50% of patients with colorectal cancer develop metastases but eventually many of them do not respond to standard therapies,"...

2014-06-17 04:21:42

Proof-of-Concept Trial Targets DNA Repair in Bile Duct Cancers SAN DIEGO and NEW TAIPEI CITY, Taiwan, June 17, 2014 /PRNewswire-iReach/ -- Senhwa Biosciences, Inc. announced today that the Company has initiated a randomized Phase 1b/2 Trial of CX-4945 in combination with gemcitabine and cisplatin for the frontline treatment of patients with bile duct cancers (cholangiocarcinoma). This Proof-of-Concept trial will study the use of CX-4945, a small molecule CK2 inhibitor, to suppress...

2014-05-14 16:28:57

-- Difficult-to-treat squamous NSCLC patients saw clinical benefit with necitumumab plus chemotherapy regimen -- INDIANAPOLIS, May 14, 2014 /PRNewswire/ -- Lung cancer patients with metastatic squamous cell carcinoma have seen few treatment advancements over the last two decades, leaving these patients with a poor prognosis. This is in contrast to the progress seen in nonsquamous non-small cell lung cancer (NSCLC).[1] Results from the largest ever Phase III trial in first-line...

2014-04-22 08:32:53

FLINT, Mich., April 22, 2014 /PRNewswire-iReach/ -- The US Food and Drug Administration has announced the expanded approval of Arzerra(®) (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia (CLL). Arzerra(®) was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy. Diplomat has access to dispense Arzerra(®). In the clinical trials results were evaluated based on...

2014-04-17 16:27:38

LONDON, April 17, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra(®) (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered...

2014-04-07 12:33:26

New data demonstrates VAL-083 is superior to standard platinum-based chemotherapy in an established in vivo model of non-small cell lung cancer (NSCLC) VANCOUVER, British Columbia, MENLO PARK, Calif. and SAN DIEGO, April 7, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014...

2014-04-04 12:18:55

Researchers from the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter, have found that an agent that inhibits mitochondrial division can overcome tumor cell resistance to a commonly used cancer drug, and that the combination of the two induces rapid and synergistic cell death. Separately, neither had an effect. These findings will be presented Monday at the annual meeting of the American Association for Cancer Research Annual Meeting 2014. "In our earlier...

2014-03-18 08:32:43

-- ABRAXANE plus gemcitabine approved by the TGA for the first-line treatment of metastatic pancreatic cancer MELBOURNE, Australia, March 18, 2014 /PRNewswire/ -- Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that ABRAXANE(®) (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the Therapeutic Goods Administration (TGA) for the first-line treatment of metastatic pancreatic cancer. The TGA approved...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related